The study and its comparison
Researchers randomized 104 adults with major depression to a supervised synthetic-psilocybin session or niacin, both with psychological support. The primary assessment was depression-score change at day 43. [1]
The psilocybin group had a larger score reduction. Sustained response, but not sustained remission, was more frequent. Overall and severe adverse events were more common, although no serious treatment-emergent events occurred. [1]
What the finding establishes
Participants with mania or psychosis histories and active suicidal intent were excluded. Results do not establish safety for those groups or unsupervised use. Usona-related funding and extensive professional relationships were disclosed. This was a supported clinical intervention, not a retail mushroom-supplement trial. [1]
A hypothetical distinction
Imagine severe adverse effects occur without an event classified as serious. Those categories should not be conflated.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.